Although gene therapy is conventionally viewed as separate from conventional pharmaceutical drug delivery, Elan Corp. plc and Targeted Genetics Corp. hope that a combination of gene delivery vectors and drug delivery technology will improve targeting of gene therapies to specific tissues.

The partners will form a new company, Emerald Gene Systems, which will be 80.1 percent owned by TGEN (Seattle, Wash.) and 19